Proteomic surveillance of retinal autoantigens in endogenous uveitis: implication of esterase D and brain-type creatine kinase as novel autoantigens

Yoko Okunuki,1,2 Yoshihiko Usui,1 Takeshi Kezuka,1 Takaaki Hattori,1 Kayo Masuko,2 Hiroshi Nakamura,2 Kazuo Yudoh,2 Hiroshi Goto,1 Masahiko Usui,2 Kusuki Nishioka,2 Tomohiro Kato,2 Masaru Takeuchi1

1Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan; 2Department of Bioregulation and Proteomics, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan

Purpose: Various retinal proteins are newly exposed to immune system in a process of tissue destructive endogenous uveitis. Some of such proteins could be autoantigens that extend the ocular inflammation in human endogenous uveitis. In this study, we aimed to investigate the possibility of such spreading of autoantigens in endogenous uveoretinitis using a proteomic approach.

Methods: Experimental autoimmune uveoretinitis (EAU) was induced in mice by inoculation with a peptide consisting of amino acids 1–20 (GPTHLFQPSLVLDMAKVLLP) of interphotoreceptor retinoid binding protein (IRBP). Six weeks after immunization, the presence of autoantibodies against the retinal proteins in mice with EAU were examined by two-dimensional electrophoresis followed by western blotting (2D-WB). Retinal proteins targeted by the autoantibodies were identified by mass spectrometry (MS) and their autoantigenicity in patients with endogenous uveitis, such as Behcet’s disease (BD, n=36), Vogt-Koyanagi-Harada disease (VKH, n=16), and sarcoidosis (n=17) were examined by enzyme-linked immunosorbent assay.

Results: Six new candidate autoantigens, which were detected in mice with EAU using 2D-WD were identified by MS as β-actin, esterase D (EsteD), tubulin β-2, brain-type creatine kinase (BB-CK), voltage-dependent anion-selective channel protein, and aspartate aminotransferase. Among the patients with endogenous uveitis, 25% of BD and 25% of VKH patients were positive for anti-EsteD antibody, and 25% of VKH and 38.4% of sarcoidosis patients were positive for anti-BB-CK antibody.

Conclusions: Autoantibodies to EsteD and BB-CK produced in EAU-induced mice were also detected in some endogenous uveitis patients, suggesting that these proteins might be autoantigens spreading in a process of endogenous uveoretinitis.
identifying circulating autoantibodies in autoimmune diseases [15,16].

In this study, we first used the interphotoreceptor retinoid protein (IRBP)-induced murine model of autoimmune uveitis (experimental autoimmune uveoretinitis, EAU) for detecting autoantigens exposed as a result of uveitis-mediated tissue destruction. We screened circulating autoantibodies in mice with EAU against the retinal proteins using 2D-WB and subsequently identified the proteins targeted by the autoantibodies using mass spectrometry (MS). We then evaluated the autoantigenicity of these identified retinal proteins in patients with endogenous uveitis (BD, VKH, and sarcoidosis).

**METHODS**

**Patients:** Serum samples were obtained from 36 BD patients with uveitis (31 men, 5 women; average age 36.9±10.5 years), 16 patients with VKH (12 men, 4 women; average age 39.2±12.6 years), and 17 patients with sarcoidosis (4 men, 13 women; average age 59.6±17.6 years). All patients were followed up by the outpatient clinic of the Department of Ophthalmology in Tokyo Medical University Hospital, Tokyo, Japan. Participants were considered to have BD if their symptoms fulfilled the diagnostic criteria of the Bechet’s Disease Research Committee of Japan [17]. At the time of sample collection, BD patients were determined to be in the active phase of the disease if they presented with one of the following indicators: iridocyclitis with hypopyon, dense vitreous opacity, obscure fundi observation, and retinal exudates with hemorrhages. All VKH patients showed typical exudative retinal detachment confirmed by fluorescein angiography. Sera were collected in these patients before aggressive systemic corticosteroid therapy was begun. Three of the VKH patients were examined when they were experiencing a recurrent phase of ocular inflammation. Ocular sarcoidosis was diagnosed based on the criteria established by the Japanese Committee for Diffuse Lung Disease for the systemic sarcoidosis [18,19]. In total, 64 healthy volunteers (35 men, 29 women), who were age- and sex-matched for each uveitis group, were recruited as healthy controls (HC). The investigation was conducted in accordance to the tenets of the Declaration of Helsinki.

**Animals and reagents:** C57BL/6 female mice, aged 6 to 9 weeks, were obtained from Sankyo Laboratory Service Corp (Tokyo, Japan). Animals were handled in accordance with the Association for the Vision and Ophthalmology statement for the use of Animals in Ophthalnic and Vision research. Horseradish peroxidase (HRP)-conjugated rabbit antimouse IgG and goat antihuman IgG were obtained from Zymed Laboratories (San Francisco, CA). Human IRBP peptide 1–20 (hIRBP-p) was synthesized by conventional solid-phase techniques on a peptide synthesizer (Takara Bio Inc., Shiga, Japan). Complete Freund’s adjuvant (CFA) and Mycobacterium tuberculosis H37Ra were purchased from Difco (Detroit, MI), Bordetella pertussis (PTX) was from Sigma-Aldrich Corp (St. Louis, MO), purified human β-actin (bAct) was from Cytoskeleton (Denver, CO), recombinant human esterase D (EsteD) was from GenWay Biotech (San Diego, CA), brain-type creatine phosphokinase (BB-CK) was from Biogenesis (Poole, England), and pETBlue-2 and Turner (DE3) pLacI competent cell were from Novagen (Darmstadt, Germany).

**Induction and scoring of experimental autoimmune uveoretinitis:** Induction of EAU in C57BL/6 mice and scoring of ocular inflammation were performed as previously described [19]. Briefly, mice were immunized subcutaneously in the occipital region with 200 μg hIRBP-p in 200 μl emulsion in CFA that had been supplemented with H37Ra to 5 mg/ml. Next, 1 μg PTX was given intraperitoneally as an additional adjuvant. On day 18 after immunization, ocular inflammation was clinically evaluated on a scale of 0 to 4 according to the previous report [20]. Briefly, minimal vasculitis with few very small lesions were scored as 0.5; mild vasculitis with 5 or less small focal choriotirenal lesions as 1; multiple (more than 5) choriotirenal lesions or severe vasculitis as 2; pattern of linear choriotirenal lesions, subretinal neovascularization, and haemorrhages as 3; and large retinal detachment and retinal atrophy as 4. The sera of the mice scoring over 1.5 were collected six weeks after immunization and used as the primary antibody in 2D-WB. Control mice were immunized with only CFA and PTX and then processed in the same way as the EAU mice.

**Protein extract preparation:** Mice were killed by cervical vertebra dislocation, and then retina from ten normal C57BL/6 female mice were separated immediately after enucleation and whole-tissue lysates were prepared by the freeze–thaw method using a lysis buffer that contained 7 M urea, 2 M thiourea, and 4% CHAPS [21]. The supernatant of each sample was collected, mixed together, and then stored at −80 °C until used.

**Two-dimensional western blotting:** Two-dimensional electrophoresis was performed as described previously [21, 22].

| Positive rate | Spot number | Control | EAU | p value* |
|--------------|-------------|---------|-----|----------|
| 103          | 0/10       | 10/10   | 5.4×10⁻⁶ |
| 30           | 2/10       | 6/10    | 0.084 |
| 71           | 2/10       | 6/10    | 0.084 |
| 131          | 0/10       | 4/10    | 0.043 |
| 29           | 0/10       | 3/10    | 0.105 |
| 34           | 0/10       | 3/10    | 0.105 |
| 59           | 0/10       | 3/10    | 0.105 |

We detected seven candidate autoantigens by comparing the positive rate of each spot between the experimental autoimmune uveoretinitis (EAU) and control by referring to the p value of the positive rate. The asterisk indicates Fisher’s exact probability test.
Figure 1. Detection of autoantigens in experimental autoimmune uveoretinitis (EAU). A: Shown is a two-dimensional gel image of murine retinal proteins stained with SYPRO Ruby. Approximately 2,000 spots were observed. Among the SYPRO Ruby stained protein spots, the 2D-WB positive spots either in control or EAU were randomly numbered. The numbers and the positions of the seven candidate autoantigens in EAU on a SYPRO Ruby stained gel are shown in panel A. The spot numbers of the candidate autoantigens are common between panel B, Table 1, and Table 2. B: Extracted murine retinal proteins were separated by two-dimensional electrophoresis, transferred onto nitrocellulose membranes. Western blotting was performed using sera from EAU or control mice. Representative membranes reacted with sera from complete Freund's adjuvant-treated control mice are shown in subpanel C, and those reacted with sera from EAU mice are shown in subpanel E. Each set of C and E subpanels shows the corresponding area. Arrowheads indicate the position of each candidate autoantigen on the EAU membranes.
22]. Briefly, 100 µg extracted protein was applied on 11 cm linear Immobiline Drystrips, pH 3–10 (GE Healthcare Bio-Science Corp., Piscataway, NJ) and rehydrated at room temperature for 10 h. Isoelectric focusing (IEF) was performed using Ettan IEPphorII (GE Healthcare Bio-Science Corp.) for 12 h. After IEF, the strips were equilibrated for 30 min in a denaturation buffer that contained 6 M urea, 2% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl, 30% glycerol, and 100 µg/ml dithiothreitol (DTT). Strips were then embedded onto 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gels, and gels were run for 2.5 h. After electrophoresis, the separated proteins on the gels were transferred onto nitrocellulose membranes. For 2D-WB, membranes were blocked in phosphate-buffered saline containing 0.1% Tween20 (PBST) for 30 min and washed three times with PBST. Next, membranes were washed with PBST before they were incubated for 1 h with 1:2000 diluted HRP rabbit antimouse IgG. Bound antibodies were visualized using diaminobenzidine (DAB; Dojindo Laboratories, Kumamoto, Japan).

**Protein identification.** Protein spots, which corresponded to the EAU-positive spots on the 2D-WB, were recovered from a 2D gel stained with SYPRO Ruby (Molecular Probes, Eugene, OR) and digested in gel with trypsin. The digested peptides were extracted from the gel pieces using trifluoroacetic acid and acetonitrile. After centrifugation, the supernatant was recovered. After three more cycles of this extraction, the supernatant was filtered and concentrated down to 10 µl in an evaporator [23,24]. Masses of the digested peptides were determined using a matrix-assisted laser desorption/ionization-time of flight mass spectrometer (MALDI-TOF MS; Ultraflex, Bruker Daltonics, Germany). A list of the determined peptide masses were subjected to mass fingerprinting by using the Mascot software program version 2.1.0 (Matrix, Science, London UK), in which the National Center for Biotechnology Information (Bethesda, MD) protein data base was searched [25]. Only those proteins with a Mowse score above statistical significant identity (p<0.05) were accepted as identified. For the proteins in which several peptides were matched, the peptide identified with the highest MOWSE score is shown.

### Table 2. Identification of candidate retinal antigens in experimental autoimmune uveoretinitis

| Spot number | Protein name                                      | NCBI accession number | Calculated MW (kDa)/pl | MOWSE scorea | Peptides matched (coverage; %) | MS/MS sequenceb |
|-------------|---------------------------------------------------|-----------------------|------------------------|--------------|-------------------------------|-----------------|
| 103         | retinol binding protein 3, interstitial           | gi|21729751               | 134/4.98               | 208             | 4 (5%)                        | IGQSNFLLTVPVSR  |
| 30          | beta-actin (bAct)                                 | gi|49868                | 39.4/5.78              | 83             | 1 (4%)                        | SYELPDQGYTIGNER |
| 71          | esterase D (EstuD)                                 | gi|55771188              | 31.8/6.70              | 52             | 3 (14%)                       | SYGQQAAEHLVLV1APDTSPR |
| 131         | tubulin beta-2 (Tub-b)                            | gi|3542680              | 50.2/4.79              | 144             | 3 (8%)                        | FPGQLNADLR      |
| 29          | creatin kinase, brain (BB-CK)                     | gi|10946574              | 42.9/5.4               | 209             | 3 (11%)                       | VLPTELYAELR     |
| 34          | voltage-dependent anion-selective channel protein | gi|10720404              | 32.5/8.55              | 39              | 1 (6%)                        | WNTDNTLGEITVEDQLAR |
| 59          | aspartate aminotransferase                        | gi|871422                | 46.4/6.68              | 142             | 4 (10%)                       | VGGVQSLGGTGALR  |

a Proteins with MOWSE score over statistical significant identity (p<0.05) were accepted as identified. bFor the proteins in which several peptides were matched, the peptide identified with the highest MOWSE score is shown.
Figure 2. The presence of antibodies to bAct, EsteD, and BB-CK in EAU mice was confirmed by 1D-WB and ELISA. A-C: Protein (2 μg) was subjected to 12.5% SDS–PAGE, transferred onto nitrocellulose membranes, then incubated with 1:200 sera from experimental autoimmune uveoretinitis (EAU) or control mice and 1:2000 horse radish peroxide (HRP) antimouse IgG as described in Methods. EAU serum samples were 8/10 positive in bAct (A), 6/10 positive in EsteD (B), and 4/10 positive in brain-type creatine kinase (BB-CK; C). D-F: Antibody titer of the sera from the EAU or control mice was determined by ELISA. The antibody titer was calculated as binding units according to the formula shown in Methods. EAU serum samples were 4/10 positive in bAct (D), 7/10 positive in EsteD (E), and 4/10 positive in BB-CK (F). Lane 1 is ponceau S staining, lane 2-4 are membranes incubated with EAU sera, and lane 5-7 are membranes incubated with control sera. In the figure, M represents molecular weight marker.
were coated with 5 μg/ml of EsteD, bAct, or BB-CK at 4 °C for 16 h in a carbonate buffer which contained 50 mM sodium carbonate. The plates were washed three times with PBST then incubated in 1% BSA-PBST at room temperature for 1 h. The plates were again washed three times, and 50 μl of 1:200 diluted serum samples were added to each well. The plates were incubated for 2 h, and then washed five times with PBST. Following incubation with 1:2000 HRP-goat anti-human IgG for 1 h, the plates were washed eight times with PBST. Color development was achieved by adding 100 μl of 0.04% o-phenylenediamine as a substrate. The reactivity of the serum sample to each protein was expressed using the arbitrary binding units, calculated according to the following formula: sample (binding units) = (OD sample / [mean OD control sera + 2SD of control sera] × 100), where OD is the optical density. According to the formula, 100 binding units were used as the cutoff point.

IgG1 and IgG2a subclasses of anti-EsteD and anti-BB-CK antibodies were determined using the mouse IgG1 and IgG2a quantitation kits (Bethyl laboratories, Montgomery, TX). Briefly, EsteD or BB-CK was coated onto the microtiter plates as described in the previous section, and serum samples diluted to 1:100 were used for the detection of IgG1 and undiluted samples were used for the detection of IgG2a.

Statistical analysis: Fisher’s exact probability test was used to compare differences in the prevalence of autoantibodies between the HC and each disease group. Fisher’s exact probability test or Student’s t-test was used to compare differences in the clinical parameters or clinical symptoms between the antibody-positive and -negative patient groups.

RESULTS
Detection of retinal autoantigens involved in experimental autoimmune uveoretinitis: EAU was induced in C57BL/6 mice by immunization with hIRBP-p. Clinical severity was evaluated 18 days after immunization. As a result, approximately 70% of hIRBP-p immunized mice developed ocular inflammation, with the clinical score of more than 1.5. We used sera from ten EAU and ten control mice to comprehensively detect retinal autoantigens by 2D-WB, and we obtained a total of 151 protein spots that reacted positively with any of the tested sera. Though the control and EAU sera
The positive rate of each spot between the EAU and control by candidate autoantigens (Figure 1A and Table 1) by comparing showed similar positive pattern on 2D-WB, we detected seven spots as candidate autoantigens whose p values were 0.105 or less. Spot positions of five major candidate autoantigens are shown in Figure 1B.

The MALDI-TOF MS and MS/MS analysis were used to identify the seven candidate autoantigens and the results of MS/MS analysis are summarized in Table 2. One spot (number 103), which reacted with 100% of the EAU sera but none of the control sera, was identified as the commonly known retinal binding protein 3 (rpb3). Rbp3 contains the 20 amino acid sequence of the hIRBP-p used for the induction of EAU. Thus, the positive reaction to this protein spot in all the EAU sera was due to the initial immunoreaction against the hIRBP-p used for immunization. It is therefore possible that the remaining six proteins were candidate retinal autoantigens induced as a result of EAU-mediated retinal destruction.

Confirmation of immunoreactivity of candidate autoantigens in experimental autoimmune uveoretinitis: Among the candidate autoantigens, we chose the four antigens, bAct, EsteD, Tub-b, and BB-CK, for further analysis. We selected bAct, EsteD, and Tub-b because their p values were low (Table 1), and BB-CK because it was a relatively retina- and brain-specific protein. To confirm the aforesaid results of the 2D-WB, we evaluated autoantibody titers against recombinant bAct, EsteD, Tub-b, and BB-CK in the EAU mice by using 1D-WB and ELISA. 1D-WB analysis showed that 8/10, 6/10, and 4/10 EAU mice were positive for autoantibodies against the antigens of bAct, EsteD, and BB-CK, respectively (Figure 2A,B,C); in contrast, none of the control mice reacted positively with any of these three antigens. Among the 25% of BD, 25% of VKH, and 17.6% of sarcoidosis sera collected six weeks after immunization (data not shown). In addition, when we compared the antibody level against bAct, EsteD, and BB-CK using the murine sera collected three, six, and ten weeks after the immunization, we found that the sera collected six weeks after the immunization had the highest levels of antibodies against these three antigens (data not shown). As Tub-b did not react with the EAU sera in either 1D-WB or ELISA (data not shown), it was not used for any further experiments.

IgG subclass of anti-EsteD and anti-BB-CK antibodies: IgGs are subclassified depending on the types of Th immune responses. Th1-mediated immune response promotes IgG2a production, while Th2-mediated immune response promotes IgG1 production. Thus, we next determined the subclass of the anti-EsteD and the anti-BB-CK antibodies. Interestingly, most of the anti-EsteD and anti-BB-CK antibodies in all the tested EAU serum samples were IgG1, and the amount of IgG2a type of the anti-EsteD and anti-BB-CK antibodies were much lower than their respective IgG1 antibodies (Figure 3). All control serum samples collected from the mice immunized without hIRBP-p were negative for both IgG1 and IgG2a (data not shown).

Autoantigenicity in human uveitis: As shown in the previous section, bAct, EsteD, and BB-CK were confirmed as retinal autoantigens in the murine model of autoimmune uveitis. Because the amino acid sequence of these three autoantigens are highly conserved in human and mouse (approximately 91–100%), we next examined whether autoantibodies against these antigens could be detected in human endogenous uveitis.

We examined the immunoreactivity against bAct, EsteD, and BB-CK by ELISA in 36 BD, 16 VKH, and 17 sarcoidosis patients with uveitis and age- and sex-matched HC. A profile of these patients is given in Table 3. Patients with the medical history of all four symptoms associated with BD (oral aphthae, skin lesion, genital ulcer, and uveitis) were 36.1%. For the VKH group, patients with active ocular inflammation before the starting of aggressive corticosteroid therapy were used, because high dose corticosteroid therapy would dramatically suppress immune response and antibody titers would also be strongly suppressed. As shown in Figure 4, EsteD reacted with the sera from 25% of BD, 25% of VKH, and 17.6% of

| Parameter                              | BD (n=36)         | VKH (n=16)        | Sarcoïdosis (n=17) |
|----------------------------------------|-------------------|-------------------|---------------------|
| Age (year)                             | 36.9±10.5         | 39.2±12.6         | 59.6±17.6           |
| Sex (Male:Female)                      | 31.5              | 8.8               | 4.1                 |
| Active ocular inflammation             | 52.8%             | 100%              | 76.4%               |
| Duration from the onset                | 4.8±4.1 (year)    | 8.8±10.5 (day)    | 6.2±5.3 (yr)        |
| LogVA                                  | -1.18±1.14        | -0.43±0.48        | -0.36±0.52          |
| Administration of systemic corticosteroid | 32.1%             | 12.5%             | 5.9%                |

In the table “duration from the onset” refers to the interval from the onset of the disease to the day when blood was collected.

TABLE 3. PROFILE OF PATIENTS WHOSE SERA WERE USED FOR ANTIBODIES DETECTION BY ELISA
sarcoidosis patients, and the percentages were significantly higher in BD (p=0.016) and VKH (p=0.015) groups than in the control group. BB-CK reacted with sera from 5.6% of BD, 25% of VKH, and 38.4% of sarcoidosis patients. Percentages were significantly higher in VKH (p=0.015) and sarcoidosis (p=0.020) groups than in the control group. One sample each in BD and sarcoidosis and two samples in VKH were positive for both EsteD and BB-CK. However, bAct did not react positively with any of the uveitis sera with any statistical significance (data not shown).

Next, we compared the clinical parameters of patients between the anti-EsteD antibody and anti-BB-CK antibody positive- and negative-patient groups in each uveitis group. As shown in Table 4, every anti-EsteD antibody positive VKH patient in this group was female. Results from this group were statistically significant compared to the anti-EsteD antibody negative VKH group (p=0.034). In the case of the BD or sarcoidosis patients, there were no statistically relevant correlations between the examined parameters (age, sex, disease duration, visual acuity, activity of ocular inflammation, serum IgG levels, systemic medications at the time of sample collection, presence of HLA-B51, or involvement of systemic diseases) and the presence of either anti-EsteD or anti-BB-CK antibody (results not shown).

**DISCUSSION**

We have identified six candidates of retinal autoantigens in EAU, out of which two, EsteD and BB-CK, showed autoantigenicity in both human endogenous uveitis and EAU. EsteD (EC 3.1.1.1) is a 282 amino acid cytoplasmic protein (31.4 kDa) that is ubiquitously expressed and functions as a nonspecific esterase. Our study showed that the murine retina expressed EsteD, and a previous work reported the presence of EsteD in human retinal pigment epithelium [27]. Considering that EsteD is expressed abundantly in other tissues such as liver, kidney, and intestine [28], there is a possibility that the anti-EsteD antibody would be found in other autoimmune diseases. However, our present study is the first to show EsteD is a target of autoimmunity in uveitis. In this study, three out of four anti-EsteD antibody-positive VKH patients were examined when they were experiencing their first episode of ocular inflammation, and one patient was examined when experiencing a recurrent phase. Our results suggest that even though VKH is a melanocyte-specific autoimmune disease, autoimmunity to antigens other than melanocyte-specific proteins are induced from the early period of uveitis, and these autoantibodies may modulate the disease. Several reports about the melanocyte-unrelated antigens in VKH support this idea [3,14]. In the VKH group, all of the anti-EsteD positive patients were female, and the
result was statistically significant. However, a larger number of patients are needed to determine that female VKH patients are commonly positive for anti-EsteD antibody.

Another retinal autoantigen detected both in EAU and human uveitis was BB-CK (EC 2.7.3.2). This is a 381 amino acid cytoplasmic enzyme (42.6 kDa) that is abundantly expressed in brain and retina, and its expression in retina has been mentioned in several reports [29,30]. Autoantibody production against BB-CK was also reported in patients with paraneoplastic sensory-dominant neuropathy [31]. Interestingly, autoantigens common to both the paraneoplastic syndrome and endogenous uveitis were reported previously. For example, it was shown that the anti-α-enolase antibody was present both in BD [9] and cancer-associated retinopathy [32-35], a paraneoplastic syndrome that affects visual function. Considering BB-CK is relatively abundant in the retina, the anti-BB-CK antibody may modulate vision-related functions in anti-BB-CK antibody-positive patients, although statistical differences in the clinical parameters were not observed in the present study.

BD, sarcoidosis, and VKH exhibit clinically distinguishable ocular manifestations, and their etiologies and pathogenesis are also different. We did not observe any statistical correlation between the patients positive for these antibodies and the disease parameters. The only distinguishing feature in this study was all anti-EsteD antibody positive patients were female. We suggest that production of anti-EsteD antibody or anti-BB-CK antibody might be unrelated to the type of uveitis—that is, regardless of the classification of uveitis, some of the patients would be positive for these antibodies. It would be worthwhile to examine a greater number of patients to further understand the roles of these autoantibodies in endogenous uveitis.

Some proteins are secondary exposed to immune system in a process of autoimmune disease. Some of such proteins could be autoantigenic and become one of the factors that extend inflammation. Several mechanisms, such as epitope spreading, molecular mimicry, and bystander activation, have been reported in various animal models of autoimmune disease and in some human autoimmune diseases [36,37]. In the present study, the anti-EsteD and anti-BB-CK antibodies were mainly of the IgG1 subclass, production of which is promoted by Th2-type cytokine. However, EAU is considered to be a Th1 disease. Therefore, it is possible that anti-EsteD and anti-BB-CK antibodies were produced as a result of Th2 immune responses promoted in the process of downregulating EAU. However, we can not define immune responses against EsteD or BB-CK in the development of endogenous uveitis with the results described in this study. We plan to study the immunogenicity including antigenicity of these proteins. In this regard, although it is a preliminary experiment, it is worth mentioning here that we have recently immunized C57BL/6 mice and Lewis rats with these two autoantigens; however, we did not observe uveitis in these animals until day 21 after immunization. This result tends to support the idea that any immune response against these two autoantigens is, indeed, a secondary reaction to tissue damage caused by the primary uveitogenic process.

Among the EAU-associated retinal autoantigens found in this study, all but BB-CK are ubiquitously and abundantly expressed proteins. These results suggest that in an underactivated immune system, even ubiquitously expressed antigens would become a target of organ-specific autoimmunity. Considering that none of the previously reported ocular-specific autoantigens in endogenous uveitis (such as S-antigen, rhodopsin [38], and recoverin [39]) were detected as candidate retinal autoantigens in the present study, ubiquitously expressed proteins appear to be more immunogenic among antigens exposed to immune system secondarily under tissue-destructive severe uveitis.

In conclusion, our study demonstrated that autoantibodies were produced against several proteins in EAU induced by immunization with an IRBP-derived peptide. Of these, autoantibodies specific for EsteD and BB-CK were also detected in human endogenous uveitis. Therefore, we suggest that EsteD and BB-CK might be autoantigens secondarily generated as a result of uveitis-induced retinal destruction. Our approach of using an animal model of autoimmune disease to comprehensively detect autoantibodies was useful in identifying new autoantigens. We believe that similar approaches will also facilitate the detection of autoantigens in other autoimmune diseases.

---

**Table 4. Statistical analysis of clinical parameters between anti-EsteD positive and negative patients of Vogt-Koyanagi-Harada disease**

| Parameter       | P (n=4) | N (n=12) | p value |
|-----------------|---------|----------|---------|
| Age (year)      | 35.8±12.7 | 42.1±10.3 | 0.41a   |
| Sex (M:F)       | 0:4     | 8:4      | 0.04b   |
| HLA-DR4         | 75% (n=4) | 77.8% (n=9) | 0.91a   |
| LogVA           | -0.49±0.61 | -0.42±0.21 | 0.54a   |
| IgG (mg/ml)     | 11.6±2.1 | 10.1±3.7 | 0.46a   |

Four anti-EsteD antibody positive Vogt-Koyanagi-Harada (VKH) patients and 12 anti-EsteD antibody negative VKH patients were statistically compared their age, sex, Log visual acuity (VA), and serum concentration of total IgG. For the analysis of HLA-DR4, four anti-EsteD antibody positive and 9 anti-EsteD antibody negative VKH patients were analysed. Age, LogVA, and serum IgG concentration were compared by Student’s t test, and sex and the presence of HLA-DR4 were compared by Fisher’s exact probability test. Anti-EsteD antibody positive VKH patients were all female and it was statistically significant compared to anti-EsteD antibody negative VKH patients. There was no statistical difference in other examined factors. *Student’s t test; †Fisher’s exact probability test.
ACKNOWLEDGMENTS

We thank Ms. Kanke, Ms. Tamaki, and Ms. Nagasawa for their technical assistance. The study was supported in part by Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (20791279).

REFERENCES

1. Direskeneli H. Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60:996-1002. [PMID: 11602462]
2. Yamaki K, Gocho K, Sakuragi S. Pathogenesis of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2002; 42:13-23. [PMID: 12189608]
3. de Smet MD, Bitar G, Mainigi S, Nussenblatt RB. Human S-antigen determinant recognition in uveitis. Invest Ophthalmol Vis Sci 2001; 42:3233-8. [PMID: 11726628]
4. de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm 2001; 9:85-92. [PMID: 11449324]
5. Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M. Cellular autoimmunity to retinal specific antigens in patients with Behcet's disease. Br J Ophthalmol 1993; 77:584-9. [PMID: 8218058]
6. de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Behcet's disease patients and controls. Invest Ophthalmol Vis Sci 2000; 41:3480-4. [PMID: 11006242]
7. Yamamoto JH, Fujino Y, Lin C, Nieda M, Juji T, Masuda K. S-antigen specific T cell clones from a patient with Behcet's disease. Br J Ophthalmol 1994; 78:927-32. [PMID: 7529558]
8. Tanaka T, Yamakawa N, Koike N, Suzuki J, Mizuno F, Usui M. Behcet's disease and antibody titers to various heat-shock protein 60s. Ocul Immunol Inflamm 1999; 7:69-74. [PMID: 10420201]
9. Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, Lee S, Bang D. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behcet's disease. Arthritis Rheum 2003; 48:2025-35. [PMID: 12847697]
10. Mor F, Weinberger A, Cohen IR. Identification of alphatropomyosin as a target self-antigen in Behcet's syndrome. Eur J Immunol 2002; 32:356-65. [PMID: 11807775]
11. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 2000; 165:7323-9. [PMID: 11120868]
12. Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2001; 42:2004-9. [PMID: 11578690]
13. Sugita S, Takase H, Taguchi C, Imai Y, Kamoi K, Kawaguchi T, Sugamoto Y, Futagami Y, Itoh K, Mochizuki M. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 2006; 47:2547-54. [PMID: 16723469]
14. Yamada K, Senju S, Shinohara T, Nakatsu T, Murata Y, Ishihara M, Nakamura S, Ohno S, Negi A, Nishimura Y. Humoral immune response directed against LEDGF in patients with VKH. Immunet Lett 2001; 78:161-8. [PMID: 11578690]
15. Okunuki Y, Usui Y, Takeuchi M, Kezuka T, Hattori T, Masuko K, Nakamura H, Yudoh K, Usui M, Nishioka K, Kato T. Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: selenium binding protein is a novel autoantigen in Behcet's disease. Exp Eye Res 2007; 84:823-31. [PMID: 17343851]
16. Xiang Y, Sekine T, Nakamura H, Imajo-Ohmi S, Fukuda H, Nishioka K, Kato T. Proteomic surveillance of autoimmunity in osteoarthritis: identification of triosephosphate isomerase as an autoantigen in patients with osteoarthritis. Arthritis Rheum 2004; 50:1511-21. [PMID: 15146421]
17. Mizushima Y. Revised diagnostic criteria for Behcet's disease in 1987. Ryunachi 1988; 28:66-70. [PMID: 3388149]
18. Yamamoto M. The concept, definition and diagnostic criteria of sarcoidosis. Nippon Rinsho 1994; 52:1426-32. [PMID: 8046818]
19. Takeuchi A, Usui Y, Takeuchi M, Hattori T, Kezuka T, Suzuki J, Okunuki Y, Iwasaki T, Haino M, Matsushima K, Usui M. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response. Invest Ophthalmol Vis Sci 2005; 46:3753-60. [PMID: 16186359]
20. Thurau SR, Chan CC, Nussenblatt RB, Caspi RR. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin Exp Immunol 1997; 109:370-6. [PMID: 9276535]
21. Toda T, Ishijima Y, Matsushita H, Yoshida M, Kimura N. Detection of thymopoietin-responsive proteins in nude mouse spleen cells by two-dimensional polyacrylamide gel electrophoresis and image processing. Electrophoresis 1994; 15:984-7. [PMID: 7813406]
22. Sanchez JC, Rouge V, Pisteur M, Ravier F, Tonella L, Moosmayer M, Wilkins MR, Hochstrasser DF. Improved and simplified in-gel sample application using reswelling of dry immobilized pH gradients. Electrophoresis 1997; 18:324-7. [PMID: 9150909]
23. Fujisawa H, Kaneko RO, Naiki M, Okada T, Masuko K, Yudoh K, Suematsu N, Okamoto K, Nishioka K, Kato T. Involvement of post-translational modification of neural plasticity-related proteins in hyperplasia revealed by a proteomic analysis. Proteomics 2008; 8:1706-19. [PMID: 18340631]
24. West KA, Yan L, Miyagi M, Crabb JS, Marmorstein AD, Marmorstein L, Crabb JW. Proteome survey of proliferating and differentiating rat RPE-J cells. Exp Eye Res 2001; 73:479-91. [PMID: 11825020]
25. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20:3551-67. [PMID: 10612281]
26. Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, Inoue T, Yamamoto K, Nishioka K, Kato T. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999; 162:4328-35. [PMID: 10201965]
27. West KA, Yan L, Shadrach K, Sun J, Hasian A, Miyagi M, Crabb JS, Hollyfield JG, Marmorstein AD, Crabb JW. Protein
database, human retinal pigment epithelium. Mol Cell Proteomics 2003; 2:37-49. [PMID: 12601081]

28. Lee WH, Wheatley W, Benedict WF, Huang CM, Lee EY. Purification, biochemical characterization, and biological function of human esterase D. Proc Natl Acad Sci USA 1986; 83:6790-4. [PMID: 3462728]

29. Hemmer W, Riesinger I, Wallimann T, Eppenberger HM, Quest AF. Brain-type creatine kinase in photoreceptor cell outer segments: role of a phosphocreatine circuit in outer segment energy metabolism and phototransduction. J Cell Sci 1993; 106:671-83. [PMID: 8282772]

30. Sistermans EA, de Kok YJ, Peters W, Ginsel LA, Jap PH, Wieringa B. Tissue- and cell-specific distribution of creatine kinase B: a new and highly specific monoclonal antibody for use in immunohistochemistry. Cell Tissue Res 1995; 280:435-46. [PMID: 7781040]

31. Arawaka S, Daimon M, Sasaki H, Suzuki JJ, Kato T. A novel autoantibody in paraneoplastic sensory-dominant neuropathy reacts with brain-type creatine kinase. Int J Mol Med 1998; 1:597-600. [PMID: 9852270]

32. Weleber RG, Watzke RC, Shults WT, Trzupek KM, Heckenlively JR, Egan RA, Adamus G. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with anti-enolase antibodies. Am J Ophthalmol 2005; 139:780-94. [PMID: 15860281]

33. Adamus G, Amundson D, Seigel GM, Machnicki M. Anti-enolase-alpha autoantibodies in cancer-associated retinopathy: epitope mapping and cytotoxicity on retinal cells. J Autoimmun 1998; 11:671-7. [PMID: 9878089]

34. Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004; 4:5. [PMID: 15180904]

35. Ren G, Adamus G. Cellular targets of anti-alpha-enolase autoantibodies of patients with autoimmune retinopathy. J Autoimmun 2004; 23:161-7. [PMID: 15324934]

36. Croxford JL, Olson JK, Miller SD. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Autoimmun Rev 2002; 1:251-60. [PMID: 12848977]

37. Deeg CA, Pompetzki D, Raith AJ, Hauck SM, Amann B, Suppmann S, Goebel TW, Olazabal U, Gerhards H, Reese S, Stangassinger M, Kaspers B, Ueffing M. Identification and functional validation of novel autoantigens in equine uveitis. Mol Cell Proteomics 2006.

38. Meyers-Elliott RH, Gammon RA, Sumner HL, Shimizu I. Experimental retinal autoimmunity (ERA) in strain 13 guinea pigs: induction of ERA-retinopathy with rhodopsin. Clin Immunol Immunopathol 1983; 27:81-95. [PMID: 6872352]

39. Gery I, Chanaud NP 3rd, Anglade E. Recoverin is highly uveitogenic in Lewis rats. Invest Ophthalmol Vis Sci 1994; 35:3342-5. [PMID: 8045724]